Dr Jacky Suen

Research Fellow

Prince Charles Hospital Northside Clinical Unit
Faculty of Medicine
j.suen1@uq.edu.au
+61 7 3139 4655

Overview

Qualifications

  • Bachelor of Science (Hons), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Publications

  • Ma, Frank Y., Han, Yingjie, Ozols, Elyce, Chew, Phyllis, Vesey, David A., Gobe, Glenda C., Morais, Christudas, Lohman, Rink-Jan, Suen, Jacky Y., Johnson, David W., Fairlie, David P. and Nikolic-Paterson, David J. (2019) Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. Nephrology, 24 9: 983-991. doi:10.1111/nep.13635

  • Ki, Katrina K., Passmore, Margaret R., Chan, Chris H. H., Malfertheiner, Maximilian V., Fanning, Jonathon P., Bouquet, Mahé, Millar, Jonathan E., Fraser, John F. and Suen, Jacky Y. (2019) Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Medicine Experimental, 7 1: 51. doi:10.1186/s40635-019-0264-z

  • Hoe, Louise E. See, Bartnikowski, Nicole, Wells, Matthew A., Suen, Jacky Y. and Fraser, John F. (2019) Hurdles to cardioprotection in the critically ill. International Journal of Molecular Sciences, 20 15: . doi:10.3390/ijms20153823

View all Publications

Supervision

  • Master Philosophy

  • Doctor Philosophy

  • Doctor Philosophy

View all Supervision

Available Projects

  • Blood transfusion is a very common procedure, often depicted in tv drama and movies, but unbeknown to the general public, it can carry significant risks to patients. For example, Transfusion-Related Acute Lung Injury (TRALI), is a serious respiratory condition that can happen to 1 in 5000 transfusion. In this study, we want to see if we can further decrease the risk of transfusion by looking at alternatives from blood products. This project involves large-animal, hypovolumic shock model and to investigate the efficacy and benefits of novel, protential alternatives.

  • Extra-Corporeal Membrane Oxygenation (ECMO) is an artificial heart/lung machine that is use to support patients with severe cardiac/respiratory failure. It has been invented for more than 30 years. To date, there is a lack of systematic examination of various parameters and settings for ECMO. Many of the current clinical practise are based on convention and tradition. This project aims to research and provide empirical evidences in order to optimise ECMO usage for patients, leading to improved patient outcome and reduced length of hospital stay. The project could involve bench-top ex vivo experiments, large animal in vivo study, and, perspective and retrospective analysis of clinical studies.

View all Available Projects

Publications

Journal Article

Conference Publication

  • Boon, A. C., Hoe, L. E. See, Pederson, S. E., Obonyo, N. G., Wells, M. A., Bartnikowski, N. J., Passmore, M. R., Marshall, L., James, L., Tung, J., Suen, J. Y., Macdonald, P. S., McGiffin, D. C. and Fraser, J. F. (2018). Inflammatory cytokine profiles in 24-hour brain stem death model. In: 38th Annual Meeting and Scientific Sessions of the International-Society-for-Heart-and-Lung-Transplantation (ISHLT), Nice, France, (S208-S208). 11-14 April 2018. doi:10.1016/j.healun.2018.01.506

  • Han, Y., Ma, F., Ozols, E., Chew, P., Vesey, D., Gobe, G., Morais, C., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2018). PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney. In: 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Sydney, Australia, (36-36). 8–12 September 2018. doi:10.1111/nep.13441

  • Tesch, G., Han, Y., Vesey, D., Gobe, G., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2016). Pharmacological Inhibition of Protease-Activated Receptor 2 (Par2) Reduces Crescent Formation in Rat Anti-Gbm Disease. In: , , (83-83). .

  • Owens, E., Iyer, A., Morais, C., Lohman, R., Suen, J., Johnson, D., Nikolic-Paterson, D., Gobe, G., Fairlie, D. and Vesey, D. (2016). Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling. In: The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth Western Australia, (86-86). 17–21 September 2016. doi:10.1111/nep.12887

  • Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015). Downsizing Proteins Without Losing Potency or Function. In: Ved Srivastava, Andrei Yudin and Michal Lebl, Proceedings of the 24th American Peptide Symposium. American Peptide Symposium 2015, Orlando , Florida, United States, (). 20-25 June 2015. doi:10.17952/24APS.2015.016

  • Yau, Annika M., Liu, Ligong, Reid, Robert C., Barry, Grant D., Suen, Jacky Y., Lohman, Rink-Jan, Le, Giang T., Cotterell, Adam and Fairlie, David P. (2011). Novel agonists and antagonists for protease activated receptor 2. In: Abstracts of Papers of the 242nd National Meeting of the American Chemical Society. National Meeting of the American Chemical Society (242nd, ACS, 2011), Denver, CO, U.S.A., (). 28 August-1 September 2011.

  • Vesey David A., Suen, Jacky Yung, Johnson, David W. and Fairlie, David (2010). A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells. In: Kidney Week, American society of Nephrology, Denver Colorado USA, (78-78). November 16 - 21.

  • Vesey, D., Rajandram, R., Blakeney, J., Suen, J., Johnson, D., Fairlie, D. and Gobe, G. (2010). Protease-activated receptor-2 and renal carcinogenesis. In: 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth Convention and Exhibition Centre, Perth, Western Australia, (91-91). 12-15 September 2010. doi:10.1111/j.1440-1797.2010.01377_1.x

  • Fairlie, David P., Madala, Praveen K., Stoermer, Martin J., Suen, Jacky, Barry, Grant and Lohman, Rink-Jan (2009). Regulating protein and peptide activated GPCRs. In: 229th National Meeting of the American Chemical Society, San Diego, California, (U106-U106). 13-17 March 2005.

Other Outputs

  • Suen, Jacky Yung (2008). Regulating protease activated Receptor 2 PhD Thesis, Institute for Molecular Bioscience, The University of Queensland. doi:10.14264/uql.2014.212

PhD and MPhil Supervision

Current Supervision

  • Master Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

Completed Supervision

Possible Research Projects

Note for students: The possible research projects listed on this page may not be comprehensive or up to date. Always feel free to contact the staff for more information, and also with your own research ideas.

  • Blood transfusion is a very common procedure, often depicted in tv drama and movies, but unbeknown to the general public, it can carry significant risks to patients. For example, Transfusion-Related Acute Lung Injury (TRALI), is a serious respiratory condition that can happen to 1 in 5000 transfusion. In this study, we want to see if we can further decrease the risk of transfusion by looking at alternatives from blood products. This project involves large-animal, hypovolumic shock model and to investigate the efficacy and benefits of novel, protential alternatives.

  • Extra-Corporeal Membrane Oxygenation (ECMO) is an artificial heart/lung machine that is use to support patients with severe cardiac/respiratory failure. It has been invented for more than 30 years. To date, there is a lack of systematic examination of various parameters and settings for ECMO. Many of the current clinical practise are based on convention and tradition. This project aims to research and provide empirical evidences in order to optimise ECMO usage for patients, leading to improved patient outcome and reduced length of hospital stay. The project could involve bench-top ex vivo experiments, large animal in vivo study, and, perspective and retrospective analysis of clinical studies.